Citations

Clear

1446 citation(s) found for "Howard, F".

Examining crossover and postprotocol therapies in first‐line immunotherapy trials in non–small cell lung cancer
Desai, Aakash , Smith, Caleb J. , Leventakos, Konstantinos , West, Howard , Pritchett, Joshua C. , Desai, Aakash P

Mayo Clinic

Cancer | February 14, 2024 | Volume: 130 | Issue: 16 | Pages: 2807-2811

10.1002/cncr.35250 | PMID 38353476 Get It

AbstractBackgroundImmune checkpoint inhibitor (ICI) therapy has led to significant improvement in outcomes for patients with nononcogene‐driven advanced non–small cell lung cancer (NSCLC). The rate of crossover and receipt of postprotocol ICI in frontline trials for advanced NSCLC has not been systematically evaluated.MethodsClinicalTrials.gov was used to identify phase 3 studies evaluating the use of immunotherapy or combination chemoimmunotherapy against chemotherapy alone in the frontline management of advanced NSCLC. Data on outcomes, rate of crossover and/or subsequent post‐protocol receipt of immunotherapy, and the start dates of these clinical trials were then extracted.ResultsTwenty‐three frontline trials in nononcogene‐driven advanced NSCLC were identified. Six trials with ICI monotherapy/dual ICI therapy and 17 trials evaluating chemotherapy/ICI in first‐line advanced NSCLC were included in the analysis. The crossover rate ranged 0% to 54% in ICI monotherapy/dual ICI trials and 0% to 52% in chemotherapy/ICI trials. Nineteen of 23 trials provided information on subsequent postprotocol therapies. Among the trials not allowing crossover, postprotocol ICI was administered to 17% to 45.8% of patients. Information regarding the eventual receipt of ICI therapy was available for 22 of 23 trials. Of 6631 patients, 2507 (37.8%) randomized to the control arm eventually received ICI therapy.ConclusionThe rate of crossover and postprotocol ICI use was low in frontline trials for first‐line NSCLC incorporating ICI. Given the proven improved overall survival of ICI in a broad population, there is a need to ensure availability of this life‐prolonging therapy in future trials, either by crossover treatment or postprotocol administration.
Abstract WP215: Number of Passes Matter in Acute Ischemic Stroke Patients Who Underwent Failed Mechanical Thrombectomy
Uchida, Kazutaka , Maier, Ilko , Kasab, Sami Al , Kim, Joon‐Tae , Quintero, Stacey C, Rai, Ansaar , Starke, Robert M. , Psychogios, Marios, Tanweer, Omar , Polifka, Adam , Park, Min S. , Levitt, Michael , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard A., Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Elawady, Sameh Samir , Cunningham, Conor M. , Matsukawa, Hidetoshi , Sowlat, Mohammad‐Mahdi , Zandpazandi, Sara , Orscelik, Atakan , Jabbour, Pascal , Psychogios, Marios‐Nikos , Shaban, Amir , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Matouk, Charles , Levitt, Michael, Williamson, Richard, Navía, Pedro , Leacy, Reade De

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.wp215 Get It

Introduction: Acute ischemic stroke (AIS) patients often require multiple passes during mechanical thrombectomy (MT) to open the vessel. Yet, at times, even numerous passes are unsuccessful. This study aims to investigate the impact of the number of passes on the outcomes of patients who underwent failed MT. Methods: We used Data from the Stroke Thrombectomy and Aneurysm Registry (STAR) from 2013 to August 2023. Patients who underwent MT for ICA, M1, or M2 with unsuccessful recanalization (modified Thrombolysis in Cerebral Infarction ≤ 2a) were included. Primary outcome was 90- day modified Rankin Scale (mRS) 0-2. Secondary outcomes included any intracranial hemorrhage (ICH) and symptomatic ICH (sICH). Outcomes were compared among patients who received ≤ 2, 3, 4, and ≥ 5 MT passes. Results: 736 patients met inclusion criteria. 90-day mRS 0-2 was found to decrease with number of passes (Figure 1). Multivariate logistic regression analysis revealed that 3 passes (OR: 0.48, 95% CI: 0.23 -0.96, P-value: 0.04), 4 passes (OR: 0.46, 95% CI: 0.19 -1.03, P-value: 0.07), and ≥ 5 passes (OR: 0.22, 95% CI: 0.08 -0.50, P-value: <0.001) were associated with lower odds of mRS 0-2 compared to ≤ 2 passes. However, there were no significant differences between groups in ICH, sICH, or 90-day mortality. Conclusion: The number of passes affects functional outcomes among stroke patients who underwent failed MT.
Abstract WP192: Impact of Second Line Thrombectomy Technique Following Failed First Pass Thrombectomy for Anterior Circulation Stroke: To Switch or Not to Switch?
Uchida, Kazutaka , Kasab, Sami Al , Maier, Ilko , Kim, Joon‐Tae , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos , Tanweer, Omar , Polifka, Adam , Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Matsukawa, Hidetoshi , Alawieh, Ali , Matouk, Charles , Sowlat, Mohammad‐Mahdi , Elawady, Sameh Samir , Jabbour, Pascal , Wolfe, Stacey Q , Samaniego, Edgar A , Arthur, Adam Stephen , Cuellar, Hugo , Howard, Brian M , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De , Yoshimura, Shinichi

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.wp192 Get It

Introduction: Despite comparable outcomes for different frontline techniques in mechanical thrombectomy (MT) for acute ischemic stroke (AIS), there are sparse data regarding if and when to switch techniques if the first pass is unsuccessful. We aimed to investigate the impact of converting from one MT technique to another on the second MT attempt for AIS among patients with large vessel occlusion (LVO). Methods: This was a retrospective observational study using data from the large multicenter international Stroke Thrombectomy and Aneurysm Registry (STAR). Data from 29 stroke centers for 10,229 AIS patients treated with MT for LVO between January 2010 and December 2022 was investigated. The primary outcome measure was successful recanalization defined as modified Thrombolysis in Cerebral Ischemia (mTICI) score of 2b or higher. 90-day modified Rankin score (mRS) 0-2, mortality and symptomatic hemorrhage were used as secondary outcomes. Clinical and technical outcomes after the second MT attempt were compared between those with or without technique conversion. Results: Among 10,229 AIS patients, 1,797 AIS patients with LVO failed first pass recanalization and were included in this retrospective analysis. 927 patients were female (52%) and median (interquartile range) age was 72 (61-81) years. Converting to alternative techniques following a first failed attempt was more likely to be associated with successful recanalization at the second attempt (adjusted odds ratio 2.30, 95% CI: 1.37-3.86, P = 0.002) and 90-day good clinical outcome (adjusted odds ratio 2.10, 95% CI: 1.15-3.85, P = 0.02) after multivariate adjustment. Conclusions: This study demonstrates better clinical and technical outcomes with conversion of MT technique for the second attempt in AIS patients with LVO who failed first pass recanalization.
Abstract WP184: Intravenous Thrombolysis Improves Outcomes in Stroke Patients With Unsuccessful Mechanical Thrombectomy
Maier, Ilko , Kasab, Sami Al , Jabbour, Pascal , Kim, Joon‐Tae , Quintero, Stacey C, Rai, Ansaar , Starke, Robert M. , Psychogios, Marios, Tanweer, Omar , Polifka, Adam , Park, Min S. , Levitt, Michael , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard A., Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Elawady, Sameh Samir , Nawabi, Noah L. A. , Matsukawa, Hidetoshi , Cunningham, Conor M. , Sowlat, Mohammad‐Mahdi , Orscelik, Atakan , Zandpazandi, Sara , Jabbour, Pascal , Psychogios, Marios‐Nikos , Samaniego, Edgar A , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Matouk, Charles , Levitt, Michael, Williamson, Richard, Navía, Pedro , Leacy, Reade De

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.wp184 Get It

Introduction: The benefits of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients with unsuccessful mechanical thrombectomy (MT) are not well established. Methods: This study included patients from the Stroke Thrombectomy and Aneurysm Registry (STAR) who underwent MT for ICA, M1, or M2 occlusions with unsuccessful MT (mTICI score ≤ 2a). Patients who received IVT prior to MT were compared to those who received MT alone. Propensity score (PS) matching was performed using age, sex, premorbid modified Rankin Scale (mRS), admission National Institute of Health Stroke Scale (NIHSS), occluded vessel, ASPECTS score, mTICI score, and symptom onset to groin puncture time. The primary outcome was favorable 90-day outcomes (mRS 0-2). Results: Of 610 patients with unsuccessful MT, 219 were matched in each group. Median ages were 70 [IQR: 61 - 80] and 73 [IQR: 62 - 81] in the IVT + MT and MT alone groups, respectively. In the IVT + MT group. Final TICI scores of 0, 1, and 2a were achieved in 92 (42.0%), 33 (15.1%), and 94 (42.9%) patients, respectively, compared to 76 (34.7%), 29 (13.2%), and 114 (52.1%) in the MT alone group. The IVT + MT group showed a significantly. higher 90-day mRS of 0-2 (aOR: 2.54, 95% CI: 1.53-4.32) and mRS of 0-3 (aOR: 2.05, 95% CI: 1.36-3.12). There were no significant differences between the groups in intracranial hemorrhage (ICH), symptomatic ICH, or 90-day mortality rates. Conclusions: IVT is associated with improved functional outcomes in patients with unsuccessful MT. Ensuring that IVT is provided to all eligible stroke patients should remain a priority.
Abstract WP180: Novel Machine Learning Model for Prediction of Futile Recanalization in Acute Ischemic Stroke Patients With Anterior Circulation Large Vessel Occlusion
Uchida, Kazutaka , Maier, Ilko , Kasab, Sami Al , Jabbour, Pascal , Kim, Joon‐Tae , Quintero, Stacey C, Rai, Ansaar , Starke, Robert M. , Psychogios, Marios, Tanweer, Omar , Polifka, Adam , Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Cunningham, Conor M. , Zohdy, Youssef M. , Elawady, Sameh Samir , Matsukawa, Hidetoshi , Sowlat, Mohammad‐Mahdi , Zandpazandi, Sara , Orscelik, Atakan , Jabbour, Pascal , Psychogios, Marios‐Nikos , Samaniego, Edgar A , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Matouk, Charles , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.wp180 Get It

Introduction: Up to 50% of acute ischemic stroke (AIS) patients who undergo successful mechanical thrombectomy (MT) fail to achieve favorable outcomes (futile recanalization). In this study we aim to develop a machine learning (ML) model to predict futile recanalization (FR) in AIS patients who undergo MT. Methods: We used data from an ongoing large, multicenter database from 2013 to 2023. We included AIS patients treated with MT for ICA, M1, or M2 occlusion with successful recanalization (modified Thrombolysis in Cerebral Infarction [mTICI] score ≥ 2C) and procedure durations under 60 minutes. FR was defined as successful recanalization with 90-day modified Rankin Scale (mRS) 3-6. The dataset was divided into 75% for training and 25% for external validation. Using the Caret Package in R, multiple models were tested, and their performances were evaluated by the area under the curve (AUC) of receiver operating. Both baseline and pre-interventional characteristics were incorporated into the model. The selected model was then externally validated on a 25% validation dataset. Results: Among 2,546 qualified patients, FR occurred in 1,342 (52.7%). In univariate analysis, baseline characteristics were significantly different between FR and non-FR groups. The M5P model demonstrated the highest performance (AUC: 0.833; 95% CI: 0.7989-0.852; PPV: 0.8101) in comparison to other tested models such as logistic regression (AUC: 0.74), RF (AUC: 0.78), J48 (AUC: 0.78), SVM (AUC: 0.79), and GB (AUC: 0.79). The external validation of the model showed satisfactory results (AUC: 75.25; 95% CI: 70-80; PPV: 76.87). Conclusion: Utilizing clinical, pre-procedural, and imaging parameters, the M5P model can efficiently predict F) in AIS patients before attempting MT. This tool can assist neurointerventionalists in adequately choosing their MT candidates.
Abstract TP198: Factors Associated With Need for Decompressive Hemicraniectomy After Mechanical Thrombectomy in Stroke Patients
Uchida, Kazutaka , Nawabi, Noah, Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Quintero, Stacey, Rai, Ansaar , Starke, Robert M. , Psychogios, Marios, Tanweer, Omar , Polifka, Adam , Park, Min S. , Levitt, Michael , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Elawady, Sameh Samir , Cunningham, Conor M. , Matsukawa, Hidetoshi , Sowlat, Mohammad‐Mahdi , Zandpazandi, Sara , Orscelik, Atakan , Jabbour, Pascal , Quintero, Stacey C, Psychogios, Marios‐Nikos , Shaban, Amir , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Matouk, Charles , Levitt, Michael, Navía, Pedro , Leacy, Reade De

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.tp198 Get It

Background: Mechanical thrombectomy (MT) has significantly reduced morbidity and mortality in acute ischemic stroke (AIS). This study aims to analyze the outcomes and factors associated with decompressive hemicraniectomy (DHC) in AIS patients who underwent MT. Methods: We retrospectively analyzed data from an ongoing, multicenter database to investigate AIS patients who underwent MT for ICA, M1, or M2 occlusion. We compared clinical and procedural variables between patients who underwent DHC and those who did not. Propensity score (PS) matching between the two groups was conducted using age, sex, admission NIHSS, occluded vessel, ASPECTS, time from symptoms onset to arterial puncture, intracranial hemorrhage (ICH), and symptomatic ICH (sICH). Results: Among the 3,135 MT patients who met our inclusion criteria, 113 underwent DHC. A 1:3 propensity matching yielded a well-matched cohort of 113 in the DHC group versus 339 in the non-DHC group. The DHC group had a significantly higher rate of successful recanalization (mTICI ≥ 2C) (175 [51.6%] versus 36 [31.9%], P < 0.001) and a longer procedure duration, with a median of 30 minutes (IQR: 17-54) compared to 44 minutes (IQR: 25-78) in the non-DHC group (P = <0.001). Further comparison of patients with low ASPECTS (≤ 5) who underwent DHC (n = 36) with those who did not (n = 99) showed no significant difference in successful recanalization rates (15 [41.7%] versus 43 [43.4%], P > 0.90). However, procedure duration was significantly longer in the DHC group with a median of 29 minutes (IQR: 13-52), compared to 39 minutes (IQR: 27-86) in the non-DHC group (P = 0.02). Conclusions: Successful recanalization can help in preventing DHC in AIS patients with high ASPECTS, but not those with low ASPECTS. Procedure duration is independently related to DHC following MT, especially in low ASPECTS patients.
Abstract TP187: Comparison of Balloon Guide Catheter versus Non-Balloon Guide Catheter for Mechanical Thrombectomy in Distal Medium Vessel Occlusion
Kallmes, David F. , Bilgin, Cem , Şenol, Yiğit Can , Maier, Ilko , Kasab, Sami Al , Kim, Joon‐Tae , Quintero, Stacey C, Rai, Ansaar , Starke, Robert M. , Psychogios, Marios, Tanweer, Omar , Polifka, Adam , Park, Min S. , Levitt, Michael , Moss, Mark, Dumont, Travis M., Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Brinjikji, Waleed , Spiotta, Alejandro M , Senol, Yigit Can , Orscelik, Atakan , Bilgin, Cem , Kobeissi, Hassan , Elawady, Sameh Samir , Cunningham, Conor M. , Matsukawa, Hidetoshi , Zandpazandi, Sara , Sowlat, Mohammad‐Mahdi , Jabbour, Pascal , Quintero, Stacey C, Psychogios, Marios‐Nikos , Samaniego, Edgar A , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele G., Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Crosa, Roberto , Matouk, Charles , Levitt, Michael, Navía, Pedro , Leacy, Reade De

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.tp187 Get It

Introduction: While balloon guide catheters (BGCs) enhance safety and efficacy of mechanical thrombectomy in large vessel occlusions, their impact on distal medium vessel occlusion (DMVO) remains underexplored. This study aimed to compare the outcomes of BGC vs non-BGC in DMVO thrombectomy. Methods: This retrospective study focused on DMVO cases defined as occlusions in M2-M4 middle cerebral artery, anterior cerebral artery, and posterior cerebral artery. Baseline characteristics and technical and clinical outcomes were compared between the two groups, with subgroup analysis in first-line thrombectomy techniques, including ADAPT, stent retriever, and Solumbra. First pass effect (FPE) was defined as a modified Thrombolysis in Cerebral Infarction (mTICI) score ≥ 2C after the first pass. Results: A total of 1,508 patients were included, of whom 231 (15.3%) were in the BGC group and 1,277 (84.7%) were in the Non-BGC group. The BGC group was associated with a lower mTICI score ≥ 2C (overall: 43.2% vs. 52.7%, p = 0.01; ADAPT: 42.2% vs. 57.1%, p = 0.01; Solumbra: 32.4% vs. 51.4%, p = 0.005), longer puncture to intracranial access time (overall: 15 vs. 8 min, p < 0.001; ADAPT: 17 vs. 8 min, p < 0.001; Solumbra: 12 vs. 8 min, p = 0.02), and longer puncture to recanalization time (overall: 97 vs. 35 min, p < 0.001; ADAPT: 100 vs. 28 min, p < 0.001; Solumbra: 78 vs. 46 min, p < 0.001; Stent retriever: 95 vs. 45 min, p < 0.001 ). The BGC group also had a lower FPE rate (17.4% vs. 30.7%, p = 0.03) in the Solumbra subgroup. In terms of clinical outcomes, the BGC group had a lower rate of distal embolization (overall: 8.8% vs. 14.9%, p = 0.02), but there were no significant differences in other clinical outcomes between the two groups in first-line thrombectomy techniques. Conclusions: Our findings showed that the use of BGC in DMVO had a lower mTICI score, reduced FPE rates, decreased distal embolization, and longer procedure times. Figure 1: Figure 2:
Staphylococcus aureus proteases trigger eosinophil-mediated skin inflammation
Kline, Sabrina N. , Orlando, Nicholas , Lee, Alex J. , Wu, Meng-Chen , Zhang, Jing , Youn, Christine , Feller, Laine , Pontaza, Cristina , Dikeman, Dustin , Limjunyawong, Nathachit , Williams, Kaitlin L. , Wang, Yu , Jacobsen, Elizabeth A. , Dong, Xinzhong , Archer, Nathan K. , Orlando, Nicholas A , Wu, Meng-Jen , Feller, Laine E , Jacobsen, Elizabeth A , Garza, Luis A , Archer, Nathan K , Nolan, Sabrina J. , Čiháková, Daniela , Durum, Scott Kenneth

Mayo Clinic

Proceedings of the National Academy of Sciences | January 30, 2024 | Volume: 121 | Issue: 6 | Pages: No page available

10.1073/pnas.2309243121 | PMID 38289950 Get It

Staphylococcus aureus skin colonization and eosinophil infiltration are associated with many inflammatory skin disorders, including atopic dermatitis, bullous pemphigoid, Netherton’s syndrome, and prurigo nodularis. However, whether there is a relationship between S. aureus and eosinophils and how this interaction influences skin inflammation is largely undefined. We show in a preclinical mouse model that S. aureus epicutaneous exposure induced eosinophil-recruiting chemokines and eosinophil infiltration into the skin. Remarkably, we found that eosinophils had a comparable contribution to the skin inflammation as T cells, in a manner dependent on eosinophil-derived IL-17A and IL-17F production. Importantly, IL-36R signaling induced CCL7-mediated eosinophil recruitment to the inflamed skin. Last, S. aureus proteases induced IL-36α expression in keratinocytes, which promoted infiltration of IL-17-producing eosinophils. Collectively, we uncovered a mechanism for S. aureus proteases to trigger eosinophil-mediated skin inflammation, which has implications in the pathogenesis of inflammatory skin diseases.
Long-term results of radiation with or without anti-androgens (AAT) in patients receiving salvage prostate bed radiation therapy (sRT) post prostatectomy.
Lukka, Himu, Pugh, Stephanie L. , Shipley, William U. , Major, Pierre , Dayes, Ian S. , Bahary, Jean-Paul , Pisansky, Thomas M. , Zeitzer, Kenneth L. , Lawton, C.A., Dess, Robert T. , Camarata, Andrew S, Balogh, Alexander G., Souhami, Luís, Seiferheld, Wendy, Feng, Felix Y. , Dess, Robert T , Dayes, Ian S , Sartor, Oliver , Efstathiou, Jason A. , Rosenthal, Seth A. , Sandler, Howard M.

Mayo Clinic

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 4_suppl | Pages: 320-320

10.1200/jco.2024.42.4_suppl.320 Get It

320 Background: sRT is used in men with prostate cancer (PC) recurrence following radical prostatectomy (RP) signaled by a persistent or delayed elevation in PSA. It was previously reported that the use of AAT with RT improved cancer control and overall survival (OS). Long-term follow-up (FU) results are presented here. Methods: From 1998to 2003, 760 eligible post-RP patients with Stage pT3N0 or with pT2N0 and positive margins and PSA from 0.2 to 4.0 ng/mL were randomly assigned on a double-blinded, placebo-controlled trial of RT + placebo vs. RT + anti-androgen therapy (AAT) (24 months of bicalutamide, 150mg daily) during and after RT (64.8 Gy in 36 fractions prostate bed). The primary endpoint was OS estimated using Kaplan-Meier method. Time to PC death and metastatic PC (competing risk of death without an event) was estimated using cumulative incidence. The hazard ratio (HR) was obtained using Cox models (OS) and subdistribution HRs (sHRs) used the Fine-Gray model (time to PC death and metastatic PC). All tests are one-sided based on study design. Results: Median FU for surviving patients was 19 years. OS at 18 years was 53% [95% confidence interval (CI): 47-58%] for RT + AAT and 43% [95% CI: 38-48%] for RT + placebo (adjusted HR 0.82 [95% CI: 0.67-1.00], p = 0.025). The 18-year incidence of centrally reviewed PC deaths were 18% [95% CI: 14-22%] RT + AAT and 28% [95% CI: 23-32%] RT + placebo (adjusted sHR = 0.57 [95% CI: 0.42-0.78], p<0.001). The 18-year incidence of metastatic PC was 22% [95% CI: 18-26%] and 31% [95% CI: 26-35%] for AAT and placebo arms respectively with adjusted sHR = 0.59 [95% CI: 0.44-0.80, p<0.001]. Subgroup analyses is shown in the Table. Conclusions: Long term results of 24-month duration AAT during and after sRT are consistent with the primary report with significantly improved long-term OS, reduced incidence of metastatic PC and PC death for RT+AAT. Statistically significant metastatic PC was noted for Gleason score 8-10, study entry PSA>1.5 and margin positive patients and borderline significance was observed in patients with study entry PSA 0.7-1.5. Clinical trial information: NCT00002874 . [Table: see text]
A phase 2/3 randomized study of CTX-009 combination in 2L biliary tract cancer: COMPANION-002.
Aranha, Olivia , Javle, Milind , Rosales, Minori Koshiji, Hu, Zishuo Ian , Faridi, Amir A., Paulson, Scott, Richards, Donald , Höchster, Howard S. , Cosgrove, David , Azad, Nilofer S. , Brown‐Glaberman, Ursa, Cline, Vivian Jean M., Shumway, Nathan M., Tejani, Mohamedtaki Abdulaziz, Nallapareddy, Sujatha, Kelley, Robin Kate , Şahin, İlyas , Borad, Mitesh J. , Goyal, Lipika

Mayo Clinic

Journal of Clinical Oncology | January 29, 2024 | Volume: 42 | Issue: 3_suppl | Pages: TPS587-TPS587

10.1200/jco.2024.42.3_suppl.tps587 Get It

TPS587 Background: Biliary tract cancer (BTC) is characterized by generally poor prognoses with limited treatment options. Systemic chemotherapy usually begins with gemcitabine, platinum agents, and a checkpoint inhibitor followed by 5-FU and oxaliplatin, irinotecan or a taxane. Presently, there is no consensus second-line therapy for patients with BTC. The DLL/Notch signaling pathway has been described to be a major driver of cholangiocarcinogenesis and VEGF-A overexpression has been reported in BTC tumors, correlating with stage, metastasis, and prognosis of the disease. CTX-009 is a recombinant bispecific antibody that binds both delta-like ligand-4 (DLL4) and vascular endothelial growth factor A (VEGF-A). The antibody simultaneously inhibits the DLL4-Notch 1 and VEGF A-VEGF receptor signaling pathways. Methods: COMPANION-002 (CTX-009 -002) is an open-label, randomized, controlled study in patients in second line advanced or metastatic BTC. To be eligible, patients must have radiologically documented progression after a prior gemcitabine and platinum containing chemotherapy regimen as first line therapy for locally advanced unresectable or metastatic disease. 150 patients will be randomized in a 2:1 ratio to receive either CTX-009 plus paclitaxel or paclitaxel alone. The stratification factors to be used at randomization include stage (locally advanced vs. metastatic), anatomic subsite of primary tumor (intrahepatic cholangiocarcinoma vs. other, i.e. extrahepatic cholangiocarcinoma, gallbladder, or ampullary), and Eastern Cooperative Oncology Group (ECOG) Performance status (0 vs. 1). Patients will be treated in 28-day cycles, with CTX-009 administered at 10 mg/kg IV on Day 1 and 15, and paclitaxel administered at 80 mg/m2 on days 1, 8, and 15. The patients randomized to paclitaxel arm can crossover after disease progression if selection criteria continue to be met. The primary objective of the study is to assess the efficacy of CTX-009 in combination with paclitaxel vs. paclitaxel alone, as measured by Overall Response Rate (ORR) assessed by an Independent Central Radiology (ICR) review. Key secondary objectives include overall survival, progression-free survival, and duration of response. Clinical trial information: 251040.